1. Home
  2. ICCM vs ATNM Comparison

ICCM vs ATNM Comparison

Compare ICCM & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.61

Market Cap

43.4M

Sector

N/A

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$1.22

Market Cap

45.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCM
ATNM
Founded
2006
2000
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.4M
45.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ICCM
ATNM
Price
$0.61
$1.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$2.50
$4.00
AVG Volume (30 Days)
250.9K
118.5K
Earning Date
11-19-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,975,000.00
$90,000.00
Revenue This Year
$19.87
N/A
Revenue Next Year
$31.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.11
52 Week Low
$0.58
$1.03
52 Week High
$1.66
$2.41

Technical Indicators

Market Signals
Indicator
ICCM
ATNM
Relative Strength Index (RSI) 38.05 39.65
Support Level $0.60 $1.15
Resistance Level $0.64 $1.29
Average True Range (ATR) 0.03 0.06
MACD -0.00 -0.01
Stochastic Oscillator 8.92 29.14

Price Performance

Historical Comparison
ICCM
ATNM

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: